Cargando…
Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats
The SARS-CoV-2 pandemic have been affecting millions of people worldwide, since the beginning of 2020. COVID-19 can cause a wide range of clinical symptoms, which varies from asymptomatic presentation to severe respiratory insufficiency, exacerbation of immune response, disseminated microthrombosis...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129034/ https://www.ncbi.nlm.nih.gov/pubmed/35609032 http://dx.doi.org/10.1371/journal.pone.0268434 |
_version_ | 1784712675452780544 |
---|---|
author | Silva, Everidiene K. V. B. Bomfim, Camila G. Barbosa, Ana P. Noda, Paloma Noronha, Irene L. Fernandes, Bianca H. V. Machado, Rafael R. G. Durigon, Edison L. Catanozi, Sergio Rodrigues, Letícia G. Pieroni, Fabiana Lima, Sérgio G. Teodoro, Walcy R. Queiroz, Zelita A. J. Silveira, Lizandre K. R. Charlie-Silva, Ives Capelozzi, Vera L. Guzzo, Cristiane R. Fanelli, Camilla |
author_facet | Silva, Everidiene K. V. B. Bomfim, Camila G. Barbosa, Ana P. Noda, Paloma Noronha, Irene L. Fernandes, Bianca H. V. Machado, Rafael R. G. Durigon, Edison L. Catanozi, Sergio Rodrigues, Letícia G. Pieroni, Fabiana Lima, Sérgio G. Teodoro, Walcy R. Queiroz, Zelita A. J. Silveira, Lizandre K. R. Charlie-Silva, Ives Capelozzi, Vera L. Guzzo, Cristiane R. Fanelli, Camilla |
author_sort | Silva, Everidiene K. V. B. |
collection | PubMed |
description | The SARS-CoV-2 pandemic have been affecting millions of people worldwide, since the beginning of 2020. COVID-19 can cause a wide range of clinical symptoms, which varies from asymptomatic presentation to severe respiratory insufficiency, exacerbation of immune response, disseminated microthrombosis and multiple organ failure, which may lead to dead. Due to the rapid spread of SARS-CoV-2, the development of vaccines to minimize COVID-19 severity in the world population is imperious. One of the employed techniques to produce vaccines against emerging viruses is the synthesis of recombinant proteins, which can be used as immunizing agents. Based on the exposed, the aim of the present study was to verify the systemic and immunological effects of IM administration of recombinant Nucleocapsid protein (NP), derived from SARS-CoV-2 and produced by this research group, in 2 different strains of rats (Rattus norvegicus); Wistar and Lewis. For this purpose, experimental animals received 4 injections of NP, once a week, and were submitted to biochemical and histological analysis. Our results showed that NP inoculations were safe for the animals, which presented no clinical symptoms of worrying side effects, nor laboratorial alterations in the main biochemical and histological parameters, suggesting the absence of toxicity induced by NP. Moreover, NP injections successfully triggered the production of specific anti-SARS-CoV-2 IgG antibodies by both Wistar and Lewis rats, showing the sensitization to have been well sufficient for the immunization of these strains of rats. Additionally, we observed the local lung activation of the Bronchus-Associated Lymphoid Tissue (BALT) of rats in the NP groups, suggesting that NP elicits specific lung immune response. Although pre-clinical and clinical studies are still required, our data support the recombinant NP produced by this research group as a potential immunizing agent for massive vaccination, and may represent advantages upon other recombinant proteins, since it seems to induce specific pulmonary protection. |
format | Online Article Text |
id | pubmed-9129034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-91290342022-05-25 Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats Silva, Everidiene K. V. B. Bomfim, Camila G. Barbosa, Ana P. Noda, Paloma Noronha, Irene L. Fernandes, Bianca H. V. Machado, Rafael R. G. Durigon, Edison L. Catanozi, Sergio Rodrigues, Letícia G. Pieroni, Fabiana Lima, Sérgio G. Teodoro, Walcy R. Queiroz, Zelita A. J. Silveira, Lizandre K. R. Charlie-Silva, Ives Capelozzi, Vera L. Guzzo, Cristiane R. Fanelli, Camilla PLoS One Research Article The SARS-CoV-2 pandemic have been affecting millions of people worldwide, since the beginning of 2020. COVID-19 can cause a wide range of clinical symptoms, which varies from asymptomatic presentation to severe respiratory insufficiency, exacerbation of immune response, disseminated microthrombosis and multiple organ failure, which may lead to dead. Due to the rapid spread of SARS-CoV-2, the development of vaccines to minimize COVID-19 severity in the world population is imperious. One of the employed techniques to produce vaccines against emerging viruses is the synthesis of recombinant proteins, which can be used as immunizing agents. Based on the exposed, the aim of the present study was to verify the systemic and immunological effects of IM administration of recombinant Nucleocapsid protein (NP), derived from SARS-CoV-2 and produced by this research group, in 2 different strains of rats (Rattus norvegicus); Wistar and Lewis. For this purpose, experimental animals received 4 injections of NP, once a week, and were submitted to biochemical and histological analysis. Our results showed that NP inoculations were safe for the animals, which presented no clinical symptoms of worrying side effects, nor laboratorial alterations in the main biochemical and histological parameters, suggesting the absence of toxicity induced by NP. Moreover, NP injections successfully triggered the production of specific anti-SARS-CoV-2 IgG antibodies by both Wistar and Lewis rats, showing the sensitization to have been well sufficient for the immunization of these strains of rats. Additionally, we observed the local lung activation of the Bronchus-Associated Lymphoid Tissue (BALT) of rats in the NP groups, suggesting that NP elicits specific lung immune response. Although pre-clinical and clinical studies are still required, our data support the recombinant NP produced by this research group as a potential immunizing agent for massive vaccination, and may represent advantages upon other recombinant proteins, since it seems to induce specific pulmonary protection. Public Library of Science 2022-05-24 /pmc/articles/PMC9129034/ /pubmed/35609032 http://dx.doi.org/10.1371/journal.pone.0268434 Text en © 2022 Silva et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Silva, Everidiene K. V. B. Bomfim, Camila G. Barbosa, Ana P. Noda, Paloma Noronha, Irene L. Fernandes, Bianca H. V. Machado, Rafael R. G. Durigon, Edison L. Catanozi, Sergio Rodrigues, Letícia G. Pieroni, Fabiana Lima, Sérgio G. Teodoro, Walcy R. Queiroz, Zelita A. J. Silveira, Lizandre K. R. Charlie-Silva, Ives Capelozzi, Vera L. Guzzo, Cristiane R. Fanelli, Camilla Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title | Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title_full | Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title_fullStr | Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title_full_unstemmed | Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title_short | Immunization with SARS-CoV-2 Nucleocapsid protein triggers a pulmonary immune response in rats |
title_sort | immunization with sars-cov-2 nucleocapsid protein triggers a pulmonary immune response in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129034/ https://www.ncbi.nlm.nih.gov/pubmed/35609032 http://dx.doi.org/10.1371/journal.pone.0268434 |
work_keys_str_mv | AT silvaeveridienekvb immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT bomfimcamilag immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT barbosaanap immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT nodapaloma immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT noronhairenel immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT fernandesbiancahv immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT machadorafaelrg immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT durigonedisonl immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT catanozisergio immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT rodriguesleticiag immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT pieronifabiana immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT limasergiog immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT teodorowalcyr immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT queirozzelitaaj immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT silveiralizandrekr immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT charliesilvaives immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT capelozziveral immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT guzzocristianer immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats AT fanellicamilla immunizationwithsarscov2nucleocapsidproteintriggersapulmonaryimmuneresponseinrats |